Pieris Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Pieris Pharmaceuticalsの CEO はSteve Yoderで、 Dec2014年に任命され、 の在任期間は 9.92年です。 の年間総報酬は$ 1.36Mで、 43%給与と57%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.006%を直接所有しており、その価値は$ 1.19K 。経営陣と取締役会の平均在任期間はそれぞれ5.2年と7年です。
主要情報
Steve Yoder
最高経営責任者
US$1.4m
報酬総額
| CEO給与比率 | 43.0% |
| CEO在任期間 | 9.9yrs |
| CEOの所有権 | 0.006% |
| 経営陣の平均在職期間 | 5.2yrs |
| 取締役会の平均在任期間 | 7yrs |
経営陣の近況
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
報酬と市場: Steveの 総報酬 ($USD 1.36M ) は、 US市場 ($USD 652.28K ) の同規模の企業の平均を上回っています。
報酬と収益: Steveの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Steve Yoder (48 yo)
9.9yrs
在職期間
US$1,358,952
報酬
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.2k | |
| Senior VP | 5.2yrs | US$729.04k | 0.018% $ 3.8k | |
| Executive Director of Investor Relations | no data | データなし | データなし | |
| Chief Supply Chain Officer | 5.1yrs | データなし | データなし |
5.2yrs
平均在職期間
48yo
平均年齢
経験豊富な経営陣: PIRSの経営陣は経験豊富で経験豊富です（平均在職期間は5.2年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.2k | |
| Independent Chairman | 7.5yrs | US$94.09k | 0.019% $ 4.0k | |
| Independent Director | 9.9yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$72.58k | 0.019% $ 4.0k | |
| Independent Director | 6.2yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.6yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし |
7.0yrs
平均在職期間
61.5yo
平均年齢
経験豊富なボード: PIRSの 取締役会 は 経験豊富 であると考えられます ( 7年の平均在任期間)。